Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay

Table 2 PCA of the fused matrix

	PC#1		PC#2		PC#3	PC#4		PC#5	PC#6
	(27,94%)		(11,46%)		(9,29%)	(7,85%)		(7,53%)	(7,02%)
Control vs no neoplasia	0,0139	*	0,0006	*******	0,1211	0,3422		0,0564	0,0001	*******
Control vs benign tumor	0,6695		0,0196	*	0,0704	0,0093	**	0,8181	0,0146
Control vs invasive cancer	0,0014	**	0,0052	**	0,1441	0,7088		0,1934	0,0006	*******
No neoplasia vs benign tumor	0,0114	*	0,6004		0,0843	0,1410		0,5076	0,5799
No neoplasia vs invasive cancer	0,0005	*******	0,9463		0,9431	0,4794		0,5665	0,4471
Benign tumor vs invasive cancer	0,0509		0,7425		0,1099	0,1423		0,6938	0,9850
Control vs no neoplasia/benign tumor	0,0300	*	0,0003	*******	0,7608	0,4215		0,1545	0,0001	*******
No neoplasia vs invasive cancer	0,0001	*******	0,8995		0,4505	0,7200		0,8283	0,5950
Control vs benign tumor/invasive cancer	0,0126	*	0,0032	**	0,5683	0,1909		0,2926	0,0003	*******
No neoplasia vs benign tumor/invasive cancer	0,0018	**	0,8412		0,5285	0,2759		0,4735	0,4262

P-values for the contrasts between the four groups (Control, no neoplasia, begin tumor and invasive cancer) were calculated for each PC#1-#6 based on PCA of the fused matrix. *: P<0.05, **: P<0.01, ***: P<0.001.

ISSN: 1476-4598